Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

185 results about "Peptide drug" patented technology

Peptide drug refers to a peptide having a specific therapeutic effect extracted by chemical synthesis, genetic recombination or animal or plant, and is a specific application of the peptide in the field of medicine.

Membrane translocating peptide drug delivery system

The present invention relates to a novel membrane translocating full-length peptide sequence, fragment, motif, derivative, analog or peptidomimetic thereof (MTLPs), to nucleotide sequences coding therefor, and to compositions comprising a MTLP-active agent complex and a MTLP-active particle complex. The MTLP or the nucleotide sequence coding therefor enhance movement of the active agent or of the active particle across a lipid membrane. More particularly, the present invention relates to a MTLP-active agent complex and a MTLP-active particle complex, wherein the MTLP enhances uptake of the active agent into a cell, into or out of an intracellular compartment and across a cell layer. Methods of making and methods of using MTLPs also are included.
Owner:MERRION RES I

Highly effective polypeptide for inhibiting angiogenesis, physical chemistry modifying method and application thereof

The invention relates to a high-performance angiogenesis inhibitor and a production method, which belongs to the field of the biological engineering pharmaceutical technology or protein polypeptide drugs. The invention designs a high-performance angiogenesis inhibitor RGD-ED with integrin compatibility, the inhibitor contains angiogenesis inhibition polypeptide isoleucine-valine-arginine-arginine-alanine-aspartate-arginine-alanine-alanine-valine-proline, and one or two ends of the inhibitor are respectively connected with polypeptides containing arginine-glycin-aspartate sequence. The RGD-ED of the invention can be synthesized. By the method of genetic engineering, the invention also expresses one of RGD-Eds in escherichia coli or other eukaryotic cells, and the RGD-ED is obtained by carrying out the separation, dissolution and renaturation of inclusion body protein and separation and purification by ion exchange chromatography. All the polypeptide sequences of the invention are modified by Polyethylene Glycol (PEG), heparin, dextran, polyvinylpyrrolidone (PVP), polyglycol-poly (amino acid) copolymer, palmitic acid, colominic acid and liposome, which includes liposome (REV), drying liposomal (DRV) and multivesicular liposome (Mvl). In vivo and in vitro experiments, the synthetic polypeptide sequence, product of genetic engineering and modified product of the invention can notably increase the effects of inhibiting the growth of endothelial cells, inhibiting angiogenesis and resisting tumor of the present angiogenesis inhibitors, and moreover, the high-performance angiogenesis inhibitor can be used as a drug curing solid tumors and rheumatoid arthritis.
Owner:CHINA PHARM UNIV

Single-effect external-cycle concentrator and application thereof

The invention discloses a single-effect external-cycle concentrator and an application thereof. The single-effect external-cycle concentrator comprises a heating chamber 1, an evaporating chamber 2, a separator I 4, a condenser 5, a cooler 6, a separator II 7 and a liquid receiver 8. The heating chamber, the evaporating chamber and the separator I are equipped with online cleaning devices respectively. The single-effect external-cycle concentrator has the advantages of a simple structure, convenience in mounting and dismounting, high evaporating efficiency, capacity of realizing online cleaning and the like, is safe and reliable in a using process, and capable of removing an organic solvent in a bone peptide crude drug liquid better. External-cycle heating is adopted, so that the heated liquid is sprayed after entering the evaporating chamber through a steam vent, and therefore, the evaporating area is increased, the solvent is quickly evaporated, and the concentration time can be shortened. Alcohol residues of the bone peptide drug liquid produced by the single-effect external-cycle concentrator are less than 10mg / ml. The single-effect external-cycle concentrator has the characteristics that a process for producing a bone peptide crude drug is easy to control, the quality of the produced bone peptide crude drug is stable, and the organic solvent residues are less.
Owner:HEBEI ZHITONG BIOLOGICAL PHARMA

Pharmaceutical in vivo dynamics characteristic-nondestructive in situ monitoring system and monitoring method

The invention relates to a system used in the internal dynamic nondestructive online checking of protein polypeptide drug, and relative checking method. The inventive system comprises a fluorescence probe and a detecting system, while the detecting system is formed by a near-infrared light source, a transmission optical fiber, a receiving optical fiber, a near-infrared high-pass filter, and a near-infrared detector. The laser of light source and the fluorescence light received by the detector can be transmitted by the optical fiber; the near-infrared band-pass or high-pass filter is at the front of detector. The invention can avoid sampling timely in the test, avoid killing animals in the organism distribution test, to and avoid the following sample treatment.
Owner:CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products